Erudio Healtherudio.com
Drug
Taletrectinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying taletrectinib: TRUST-III. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| TRUST-III NCT06564324 · Nuvation Bio Inc. | TKI-naïve ROS1-positive locally advanced/metastatic non-small cell lung cancer | Phase 3 | 12 | 3 | Focused | Nov 19, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| TRUST-II NCT04919811 · Nuvation Bio Inc. DeepView → | advanced or metastatic ROS1-positive non-small cell lung cancer | Phase 2 | Deep | View | |||